Aortic Stent Graft Market to Reach USD 5.9 Billion by 2035

According to analysts at Vantage Market Research, the Global Aortic Stent Graft Market size is worth USD 3.8 Billion in 2024 and is projected to reach USD 5.9 Billion by 2035, growing at a CAGR (Compound Annual Growth Rate) of 5.7% from 2024 to 2035. Key trends of market include technological advancement, minimally invasive procedure, improved imaging and diagnostics, aging population, and regulatory approvals and reimbursement. 

Market Overview

The market is driven by increasing incidence of aortic aneurysms and the rising demand for minimally invasive procedures such as endovascular repairs. Furthermore, technological advancements and strategic activities by the manufacturers are expected to bring new aortic stent grafts market trends in the coming years. According to World Health Organization, most people in the WHO European Region consume far too much salt, and more than one in three adults aged 30–79 has hypertension, the medical term for high blood pressure. This matters because high salt intake raises blood pressure, which is a leading risk factor for cardiovascular diseases such as heart attacks and strokes. 

The growing geriatric population is a crucial driver of aortic stent graft market. The factors such as older individuals are more susceptible to aortic diseases, including aneurysms. According to the United Nations, the proportion of people aged 65 years and above is increasing at a faster rate than those below that age. This means that the percentage of the global population aged 65 and above is expected to rise from 10% in 2022 to 16% in 2050. It is projected that by 2050, the number of individuals aged 65 years or above across the world will be twice the number of children under age 5 and almost equivalent to the number of children under 12 years.

Terumo India launches TREO® Abdominal Stent-graft system

• In August 2024, Terumo India, the Indian subsidiary of Terumo Corporation (TSE: 4543), a global leader in medical technology, today announced the launch of the TREO® Stent-Graft System, an advanced solution for Endovascular Aneurysm Repair (EVAR). Designed specifically for the treatment of infrarenal abdominal aortic aneurysms in adults with suitable anatomies, the TREO® Stent-Graft System stands out as the only EVAR graft featuring both suprarenal and infrarenal active fixation

Key Takeaways from the Report

• North America dominated the market with largest market share of 38.9% in 2024. Market is driven by technological improvements, rising aortic aneurysm cases, and robust financial incentives
• In 2024, based on the Product Type, the Abdominal aortic stent graft category accounted for significant market share of 62.5%. The segment growth is driven by an increase in the geriatric population and the rise of abdominal aortic aneurysm
• In 2024, based on the End User, the Hospitals category holds the largest market share. The segment is driven by the availability of advanced facilities and the continuous growth of healthcare infrastructure within hospitals

Top Companies

• Cryolife Inc
• Cook Medical Inc
• Lombard Medical Inc
• Becton, Dickinson and Company
• Medtronic Inc
• W.l. Gore & Associates
• Cardinal Health
• Bolton Medical
• Endologix Inc
• Microport Scientific Corporation Inc
• JOTEC

Report Coverage

Our market research reports provide comprehensive insights that are essential for strategic decision-making. We cover all key aspects of the market, including dynamics such as drivers, restraints, opportunities, and challenges, alongside the latest industry trends. Our analysis includes an in-depth technology roadmap, product life cycle evaluation, and PESTLE analysis, ensuring a thorough understanding of the market environment. We also assess GDP growth outlooks, examine regional market landscapes, and evaluate the impact of major events like the COVID-19 pandemic. Additionally, our reports feature a detailed competitive landscape, including company market shares and profiles, providing actionable intelligence to empower your business strategies.

Latest News

W. L. Gore & Associates, Inc. Receives U.S. Food & Drug Administration (FDA) Approval for Lower Profile GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis, now 6 Fr Sheath Compatible

• In January 2024, as part of efforts to continuously improve medical solutions for patients with complex vascular disease, W. L. Gore & Associates, Inc. (Gore) announced recent FDA approval of a lower profile GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis (VBX Stent Graft). FDA approval of this innovation builds on a proven device which has become an important tool for treating complex vascular disease. In addition to offering the longest balloon expandable stent on the market with its 79 mm configuration, and the widest range of stent diameter adjustability, the VBX Stent Graft now also offers the most 6 Fr compatible configurations among balloon expandable stent grafts